CCP-Anastrozole · DIN 02458799 · 1 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2023-08-03 — choose a marketed DIN from the same-category list.Discontinued August 3, 2023 · checked November 17, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2023-08-03 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2023-08-03 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
CCP-Anastrozole · DIN 02458799
Manufacturer: CellChem Pharmaceuticals Inc.; listing date 2017-12-21
Health Canada: Cancelled post market since 2023-08-03 · brand CCP-ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Cellchem pharmaceuticals inc. · schedule Prescription
CCP-Anastrozole: Formulary list price $0.95 per unit (the source does not state the unit; exact figure $0.9522). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02458799)
Source record
DIN 02458799: CCP-Anastrozole
Raw flags: sec3=Y
Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id CCP
Source form: Tab; strength: 1mg
Recorded listing: General benefit
Source prices (unrounded): $0.9522; ministry $0.9522
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02458799
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94594
Interchangeable products
Anastrozole · DIN 02351218 · $0.9522
Anastrozole · DIN 02442736 · $0.9522
Anastrozole · DIN 02529904 · $0.9522
Apo-Anastrozole · DIN 02374420 · $0.9522
Arimidex · DIN 02224135 · $0.9522
Co Anastrozole · DIN 02394898 · $0.9522
Jamp Anastrozole Tablets · DIN 02540584 · $0.9522
Jamp-Anastrozole · DIN 02339080 · $0.9522
Mar-Anastrozole · DIN 02379562 · $0.9522
Med-Anastrozole · DIN 02379104 · $0.9522
Mint-Anastrozole · DIN 02393573 · $0.9522
Nat-Anastrozole · DIN 02417855 · $0.9522
PMS-Anastrozole · DIN 02320738 · $0.9522
Ran-Anastrozole · DIN 02328690 · $0.9522
Riva-Anastrozole · DIN 02392259 · $0.9522
Sandoz Anastrozole · DIN 02338467 · $0.9522
Taro-Anastrozole · DIN 02365650 · $0.9522
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since August 3, 2023 — choose a marketed DIN from the same-category list.